Resources

Dr. Sami Khella, Professor of Neurology and co-founder of the Amyloidosis Program at the University of Pennsylvania discussed the latest in diagnosis, treatment, and management of neuropathy and amyloidosis.

ARC Executive Director of Research Kristen Hsu presented an overview of the different approaches to treating ATTR amyloidosis, as well as the most current updates for the clinical trial landscape, with a focus on ATTR trials.

Dr. Jan Griffin, amyloidosis cardiologist at the Medical University of South Carolina, discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.

This white paper summarizes advancements in the field, key challenges, and consensus priorities for the amyloidosis research community that were identified and discussed by attendees of the 2024 ARC Research Roundtable Meeting. The information presented in this paper represents the opinions and outlooks of the global amyloidosis experts.

Sabrina Rebello, ARC's Senior Research Manager, presented an in-depth overview of key insights from our Annual Community Survey. This webinar focused on understanding the experiences of patients and caregivers throughout their diagnostic journey and ongoing care.

Lovley, A., Hsu, K., LaGasse, K. et al. Reliability and validity of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire impact scales. J Patient Rep Outcomes 9, 44 (2025). https://doi.org/10.1186/s41687-025-00880-7

Kristen Hsu, ARC’s Executive Director of Research, presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.

Dr. Meghan Beier, psychologist at the Rowan Center for Behavioral Medicine, explored the emotional aspects of amyloidosis. She discussed mental health issues in amyloidosis and present strategies for coping.